Granahan Investment Management LLC Grows Stock Holdings in GeneDx Holdings Corp. $WGS

Granahan Investment Management LLC raised its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 212.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 96,605 shares of the company’s stock after acquiring an additional 65,695 shares during the quarter. Granahan Investment Management LLC’s holdings in GeneDx were worth $6,204,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Arizona State Retirement System grew its position in shares of GeneDx by 2.1% in the 4th quarter. Arizona State Retirement System now owns 5,594 shares of the company’s stock valued at $728,000 after buying an additional 113 shares during the last quarter. Cerity Partners LLC lifted its position in GeneDx by 6.0% in the fourth quarter. Cerity Partners LLC now owns 2,527 shares of the company’s stock valued at $329,000 after acquiring an additional 142 shares during the last quarter. Main Management ETF Advisors LLC boosted its stake in GeneDx by 1.0% in the fourth quarter. Main Management ETF Advisors LLC now owns 15,660 shares of the company’s stock valued at $2,037,000 after acquiring an additional 160 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in GeneDx by 5.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company’s stock valued at $399,000 after acquiring an additional 181 shares in the last quarter. Finally, Strs Ohio grew its holdings in shares of GeneDx by 8.7% during the first quarter. Strs Ohio now owns 2,500 shares of the company’s stock worth $161,000 after purchasing an additional 200 shares during the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Analyst Ratings Changes

WGS has been the topic of several research analyst reports. Weiss Ratings lowered GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Zacks Research downgraded GeneDx from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Guggenheim restated a “buy” rating and set a $74.00 target price (up from $70.00) on shares of GeneDx in a research report on Monday, June 29th. Wall Street Zen cut shares of GeneDx from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Craig Hallum reiterated a “buy” rating and issued a $85.00 price target on shares of GeneDx in a research report on Tuesday, May 5th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $87.43.

GeneDx News Summary

Here are the key news stories impacting GeneDx this week:

• Neutral Sentiment: Multiple law firms reiterated that a securities class action has been filed against GeneDx and certain executives, with the case centered on alleged misstatements about the Fabric Genomics acquisition and related synergies. Article: WGS DEADLINE ALERT: GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit- August 3, 2026 Deadline
• Negative Sentiment: Several firms highlighted that investors have until August 3, 2026 to seek lead-plaintiff status, keeping the lawsuit in focus and potentially increasing overhang on the stock. Article: WGS 10-DAY DEADLINE ALERT: GeneDx Holdings Corp. (NASDAQ: WGS) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 3, 2026 Lead Plaintiff Deadline
• Negative Sentiment: Attorney promotions and investor alerts also pointed to the sharp stock selloff after GeneDx’s May earnings update, which disclosed a large impairment charge and weaker guidance, reinforcing concerns about prior disclosures and fundamentals. Article: Lost Money on GeneDx Holdings Corp. (WGS)? Join Class Action Suit Seeking Recovery – Contact SueWallSt

Insider Activity

In other news, Director Keith A. Meister bought 46,273 shares of the stock in a transaction dated Friday, May 15th. The shares were acquired at an average price of $38.91 per share, with a total value of $1,800,482.43. Following the completion of the acquisition, the director directly owned 4,784,570 shares in the company, valued at approximately $186,167,618.70. The trade was a 0.98% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Kevin Feeley sold 3,729 shares of the business’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $60.77, for a total transaction of $226,611.33. Following the transaction, the chief financial officer owned 39,954 shares in the company, valued at approximately $2,428,004.58. This trade represents a 8.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have purchased 2,256,420 shares of company stock worth $93,144,340 and have sold 21,699 shares worth $1,295,646. Company insiders own 25.17% of the company’s stock.

GeneDx Price Performance

GeneDx stock opened at $59.10 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95. The business has a 50 day simple moving average of $58.75 and a 200-day simple moving average of $72.43. GeneDx Holdings Corp. has a 12 month low of $32.21 and a 12 month high of $170.87. The stock has a market capitalization of $1.75 billion, a PE ratio of -22.05 and a beta of 1.90.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The firm had revenue of $102.25 million during the quarter, compared to analysts’ expectations of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same quarter last year, the business earned ($0.23) earnings per share. Equities analysts predict that GeneDx Holdings Corp. will post -1 earnings per share for the current year.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.